Synergy IB Investment Invests 3 Billion KRW in Genomictree Convertible Bonds

[Asia Economy Reporter Jang Hyowon] Synergy Partners Group's new technology finance company, Synergy IB Investment, announced on the 22nd that it will invest 3 billion KRW in Genomictree convertible bonds (CB).

Genomictree is a bio healthcare company specializing in early cancer diagnosis, manufacturing and selling in vitro early cancer diagnostic kits. Synergy IB Investment considered Genomictree's sound financial status and its differentiated high technology in the early cancer diagnosis market as key investment points.

As the first operator of Korea Bio TIPS, Synergy IB Investment has a track record of investing from TIPS investment to follow-up investments in various bio healthcare companies such as Aptabio, and secures expertise in bio healthcare investment through verification and collaboration with Synergy Partners Group's bio and pharmaceutical affiliates, including Synergy Innovation.

Meanwhile, including this investment, Synergy IB Investment has invested a total of 51.5 billion KRW in 14 companies this year, and plans to expand investments into various fields such as bio healthcare with technological capabilities in existing materials, parts and equipment, green new deal, and 4th industry sectors.